

Winning Entry:

From Rejection to Recommendation: Overturning a NICE Decision to Improve Patient Access



Martin Furze Sanofi



Charlotte Sugden Heron Synergy Healthcare Research



Matthew Bradberry Sanofi



Amy Page Synergy Healthcare Research



Luke Skinner Sanofi



Larissa Dempsey Synergy Healthcare Research

Supporting team: Katharina Ecsy, Sanofi Arunesh Sil, Sanofi Richard Hudson, Sanofi

Best Business Impact

Awarded for a research or analytical project that has demonstrated a significant impact on the client's UK business

"As a champion for turning data and insights into tangible actions in order to bring about meaningful change, CREATION.co is delighted to continue sponsoring the BHBIA's BOBI award 'Best Business Impact'. Since 1998, our insights and consulting have informed the strategies of the world's largest healthcare companies and we are excited to recognise those who also desire to bring about business impact, bettering the lives and experiences of patients, healthcare professionals and wider health stakeholders."

Winners' Statement

"A huge thank you to all the patients and carers who participated. NICE's decision reversal is a huge benefit for patients, who would not have been able to access this new treatment had the initial draft negative NICE assessment not been overturned."

Executive Summary

What happens when NICE publishes draft guidance that does not recommend use of your new medication, due to a lack of quality-of-life data in the target patient population?

We went and conducted new research to collect the necessary data needed to challenge the decision.

Research was designed, in partnership with a leading UK charity, to gather data from a small patient population with significant quality-of-life issues and lack of treatment options.

The data helped contribute to overturning NICE's draft decision – giving more patients access to a much-needed new treatment option.







